Comparative Pharmacology
Head-to-head clinical analysis: DI ATRO versus MYTESI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DI ATRO versus MYTESI.
DI-ATRO vs MYTESI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ipratropium bromide is an anticholinergic agent that antagonizes muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in bronchial smooth muscle, thereby inhibiting vagally-mediated bronchoconstriction and reducing mucus secretion. Albuterol sulfate is a beta-2 adrenergic receptor agonist that activates adenylyl cyclase, increasing cyclic AMP levels, leading to bronchodilation.
MYTESI (crofelemer) is a proanthocyanidin oligomer that acts locally in the gastrointestinal tract to inhibit chloride ion secretion by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC) at the luminal surface of enterocytes, thereby reducing fluid and electrolyte secretion.
Ipratropium bromide inhalation aerosol: 500 mcg (2 puffs) 3-4 times daily; maximum 2000 mcg (8 puffs) per day. Ipratropium bromide nebulizer solution: 500 mcg per nebulization 3-4 times daily.
1 capsule (5 mg) orally three times daily, taken 30 minutes before meals.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
1.6 hours (mean terminal elimination half-life); clinical context: short half-life supports oral administration three times daily to maintain therapeutic levels.
Renal (80% as unchanged drug), biliary/fecal (20%)
Primarily fecal (82-86%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category C
Category C
Antidiarrheal
Antidiarrheal